Probiodrug looks to IPO for $40M to fund Alzheimer's work; PTC raises $109M in follow-on;

@FierceBiotech: 2014's most successful biotech IPOs. Special report | Follow @FierceBiotech

@JohnCFierce: ICYMI: Gilead wins FDA approval for its hep C combo pill, a blockbuster in the making. Article | Follow @JohnCFierce

@DamianFierce: And finally, wins FDA approval for Harvoni. Release | Follow @DamianFierce

@EmilyMFierce: What It's Like to Carry Your Nobel Prize through Airport Security. Article from Scientific American | Follow @EmilyMFierce

> Germany's Probiodrug is looking to raise about $40 million in its IPO on the Amsterdam exchange. The biotech is focused on Alzheimer's. Story

> PTC Therapeutics ($PTCT) has raised about $109 million in a follow-on offering. Release

Medical Device News

@FierceMedDev: ICYMI Friday: Deerfield bets up to $125M on nuclear materials used in imaging. Article | Follow @FierceMedDev

@VarunSaxena2: Report warns of cyberattacks against medical devices to extort money. More | Follow @VarunSaxena2

@EmilyWFierce: Device from Bay Area startup detects microRNA in blood to screen for dozens of cancers. Story via Wired | Follow @EmilyWFierce

@MichaelGFierce: With Roche's Herceptin, green tea component doubles drug accumulation in cancer cells. FierceDrugDelivery story | Follow @MichaelGFierce

> PAD patients gain another treatment option as the FDA approves its first drug-coated balloon. Story

> Harvard scientists develop super-repellent coating technology for commonly used devices. Report

Pharma News

@FiercePharma: Top-read news this weekend: Bayer resolves 200 Trasylol lawsuits. Article | Follow @FiercePharma

@EricPFierce:  | Follow @EricPFierce

@CarlyHFierce: ICYMI: Novartis employee pleads guilty to bribery in Poland. Story | Follow @CarlyHFierce

> Texas AG: AstraZeneca paid $465K in kickbacks, committed fraud in Seroquel marketing. News

> Payers hit back at Gilead for $94,500 price tag on brand-new hep C combo pill. Article

> Eisai adds to chemo side-effects franchise with FDA nod for Akynzeo. Story

CRO News

> Catalent reaches out to lung cancer patients with research agreement. Item

> Covance and Novartis team up with eyes on Big Data. Article

> Parexel expands in the U.K. after an eClinical buyout. Story

> Clinipace raises $4M after staging 5 buyouts in 5 years. More

> With help from Charles River, AstraZeneca expands its respiratory pipeline. Report

Biotech IT News

> Merck's VC unit invests in data security business. More

> ISB teams with Google for NCI Cancer Genomics Cloud project. Report

> NIH turns on Big Data funding faucet. Story

> Merck and Pfizer join Accenture's Life Sciences Cloud Coalition. News

> VC shop follows Y Combinator into the world of biotech incubators. Article

Animal Health News

> Chronic wasting disease found in Iowa captive deer population. Item

> U.K.'s Pirbright Institute tabbed for $29M in funding to train vet scientists. More

> Pan Genome Systems searching for money to fund new Johne's disease vaccine. Article

> UC Davis researchers solve century-old bluetongue virus mystery. Story

> Three European companies will team to develop VLP vaccines for vet use. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.